

Giota Touloumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5244079/publications.pdf>

Version: 2024-02-01

155
papers

15,124
citations

46984

47
h-index

19169

118
g-index

162
all docs

162
docs citations

162
times ranked

24876
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir for the Treatment of Covid-19 – Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	13.9	5,834
2	Confounding and Effect Modification in the Short-Term Effects of Ambient Particles on Total Mortality: Results from 29 European Cities within the APHEA2 Project. Epidemiology, 2001, 12, 521-531.	1.2	810
3	Acute Effects of Particulate Air Pollution on Respiratory Admissions. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1860-1866.	2.5	566
4	Acute Effects of Ozone on Mortality from the –Air Pollution and Health. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1080-1087.	2.5	397
5	Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. European Respiratory Journal, 1997, 10, 1064-1071.	3.1	333
6	Acute Effects of Ambient Particulate Matter on Mortality in Europe and North America: Results from the APHENA Study. Environmental Health Perspectives, 2008, 116, 1480-1486.	2.8	331
7	Methodological issues in studies of air pollution and daily counts of deaths or hospital admissions.. Journal of Epidemiology and Community Health, 1996, 50, S3-S11.	2.0	327
8	Short term effects of air pollution on health: a European approach using epidemiologic time series data: the APHEA protocol.. Journal of Epidemiology and Community Health, 1996, 50, S12-S18.	2.0	313
9	Estimating the Exposure–Response Relationships between Particulate Matter and Mortality within the APHEA Multicity Project. Environmental Health Perspectives, 2005, 113, 88-95.	2.8	263
10	Short-term effects of nitrogen dioxide on mortality: an analysis within the APHEA project. European Respiratory Journal, 2006, 27, 1129-1138.	3.1	261
11	Urban air pollution and emergency admissions for asthma in four European cities: the APHEA Project. Thorax, 1997, 52, 760-765.	2.7	251
12	The temporal pattern of respiratory and heart disease mortality in response to air pollution.. Environmental Health Perspectives, 2003, 111, 1188-1193.	2.8	238
13	Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology, 2016, 63, 1481-1492.	3.6	215
14	Short-term Effects of Ambient Oxidant Exposure on Mortality: A Combined Analysis within the APHEA Project. American Journal of Epidemiology, 1997, 146, 177-185.	1.6	205
15	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm ³ : Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	2.9	180
16	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut, 2011, 60, 1109-1116.	6.1	159
17	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
18	Short-Term Effects of Air Pollution on Daily Mortality in Athens: A Time-Series Analysis. International Journal of Epidemiology, 1994, 23, 957-967.	0.9	118

#	ARTICLE	IF	CITATIONS
19	Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. <i>Journal of Hepatology</i> , 2013, 59, 949-956.	1.8	107
20	High levels of postmigration HIV acquisition within nine European countries. <i>Aids</i> , 2017, 31, 1979-1988.	1.0	105
21	THE 1987 ATHENS HEATWAVE. <i>Lancet, The</i> , 1988, 332, 573.	6.3	102
22	Daily mortality and "winter type" air pollution in Athens, Greece--a time series analysis within the APHEA project.. <i>Journal of Epidemiology and Community Health</i> , 1996, 50, s47-s51.	2.0	102
23	Practical methods for competing risks data: A review. <i>Statistical Methods in Medical Research</i> , 2012, 21, 257-272.	0.7	99
24	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 951-963.	5.2	99
25	Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2000, 109, 628-634.	0.6	98
26	Effect of recent thymic emigrants on progression of HIV-1 disease. <i>Lancet, The</i> , 2000, 355, 599-604.	6.3	94
27	Analysis of health outcome time series data in epidemiological studies. <i>Environmetrics</i> , 2004, 15, 101-117.	0.6	88
28	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	2.9	88
29	Short-Term Effects of Carbon Monoxide on Mortality: An Analysis within the APHEA Project. <i>Environmental Health Perspectives</i> , 2007, 115, 1578-1583.	2.8	87
30	Acute effects of ambient ozone on mortality in Europe and North America: results from the APHENA study. <i>Air Quality, Atmosphere and Health</i> , 2013, 6, 445-453.	1.5	87
31	Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA Load. <i>Journal of Virology</i> , 2002, 76, 10099-10108.	1.5	84
32	A survey of bloodborne viruses and associated risk behaviours in Greek prisons. <i>Addiction</i> , 1998, 93, 243-251.	1.7	83
33	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	6.3	82
34	MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 3099.	1.4	81
35	Investigating regional differences in short-term effects of air pollution on daily mortality in the APHEA project: a sensitivity analysis for controlling long-term trends and seasonality.. <i>Environmental Health Perspectives</i> , 2001, 109, 349-353.	2.8	75
36	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	1.6	75

#	ARTICLE	IF	CITATIONS
37	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. <i>International Journal of Epidemiology</i> , 2002, 31, 951-958.	0.9	64
38	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 2029-2037.	1.0	64
39	Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. , 1999, 18, 1215-1233.		62
40	Attitudes of a Mediterranean population to the truth-telling issue.. <i>Journal of Medical Ethics</i> , 1992, 18, 67-74.	1.0	61
41	Air pollution and cause specific mortality in Athens.. <i>Journal of Epidemiology and Community Health</i> , 1990, 44, 321-324.	2.0	60
42	Seasonal confounding in air pollution and health time-series studies: effect on air pollution effect estimates. <i>Statistics in Medicine</i> , 2006, 25, 4164-4178.	0.8	60
43	Investigating the dose-response relation between air pollution and total mortality in the APHEA-2 multicity project. <i>Occupational and Environmental Medicine</i> , 2003, 60, 977-982.	1.3	58
44	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. <i>Aids</i> , 2004, 18, 1697-1705.	1.0	56
45	Psychotic (delusional) depression and suicidal attempts: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 18-29.	2.2	56
46	Effects of Lead on the Somatic Growth of Children. <i>Archives of Environmental Health</i> , 1997, 52, 377-383.	0.4	52
47	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV</i> , 2015, 2, e335-e343.	2.1	52
48	Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation study. <i>Statistics in Medicine</i> , 2001, 20, 3715-3728.	0.8	50
49	Impact of Missing Data Due to Selective Dropouts in Cohort Studies and Clinical Trials. <i>Epidemiology</i> , 2002, 13, 347-355.	1.2	50
50	The temporal pattern of mortality responses to ambient ozone in the APHEA project. <i>Journal of Epidemiology and Community Health</i> , 2009, 63, 960-966.	2.0	47
51	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	2.9	46
52	Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: A case-control study. , 1996, 68, 51-53.		45
53	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	1.0	45
54	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. <i>Aids</i> , 2004, 18, 2261-2267.	1.0	44

#	ARTICLE	IF	CITATIONS
55	Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. <i>Journal of Viral Hepatitis</i> , 2004, 11, 366-374.	1.0	44
56	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	2.9	44
57	Short-Term Effects of Air Pollution on Total and Cardiovascular Mortality. <i>Epidemiology</i> , 2005, 16, 49-57.	1.2	43
58	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	0.9	43
59	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , 2019, 17, 4.	2.3	43
60	Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. <i>HIV Medicine</i> , 2018, 19, 184-194.	1.0	41
61	Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. <i>Annals of General Psychiatry</i> , 2018, 17, 39.	1.2	41
62	Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. <i>Aids</i> , 1998, 12, 1691-1697.	1.0	39
63	Delayed HIV diagnosis and initiation of antiretroviral therapy. <i>Aids</i> , 2014, 28, 2297-2306.	1.0	39
64	Hepatocellular carcinoma risk in HBsAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 120-127.	1.0	38
65	The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. , 1999, 82, 817-821.		37
66	Modelling competing risks data with missing cause of failure. <i>Statistics in Medicine</i> , 2010, 29, 3172-3185.	0.8	36
67	The epidemiologic profile of Kaposi's sarcoma in Greece prior to and during the AIDS era. <i>International Journal of Cancer</i> , 1997, 70, 538-541.	2.3	33
68	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV</i> , 2014, 1, e119-e126.	2.1	32
69	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
70	Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. <i>PLoS ONE</i> , 2012, 7, e32369.	1.1	30
71	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. <i>Journal of Viral Hepatitis</i> , 2005, 12, 543-550.	1.0	29
72	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. <i>Aids</i> , 2010, 24, 2697-2704.	1.0	29

#	ARTICLE	IF	CITATIONS
73	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 28-37.	0.9	29
74	A randomized trial comparing concise and standard consent forms in the START trial. <i>PLoS ONE</i> , 2017, 12, e0172607.	1.1	28
75	HIV testing history and access to treatment among migrants living with HIV in Europe. <i>Journal of the International AIDS Society</i> , 2018, 21, e25123.	1.2	27
76	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. <i>Aids</i> , 2007, 21, 1283-1291.	1.0	26
77	The effect of antiretroviral treatment of different durations in primary HIV infection. <i>Aids</i> , 2008, 22, 2441-2450.	1.0	26
78	Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. <i>Hippokratia</i> , 2011, 15, 26-31.	0.3	26
79	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece. <i>PLoS ONE</i> , 2020, 15, e0230730.	1.1	24
80	Barriers to health care services for migrants living with HIV in Spain. <i>European Journal of Public Health</i> , 2018, 28, 451-457.	0.1	23
81	High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey. <i>BMC Public Health</i> , 2020, 20, 1665.	1.2	21
82	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2005, 54, 405-423.	0.5	20
83	Natural course of treated and untreated chronic HCV infection: results of the nationwide HEPNET-GREECE cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1121-1130.	1.9	20
84	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
85	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. <i>Aids</i> , 2019, 33, 133-143.	1.0	20
86	Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. <i>Journal of Virological Methods</i> , 2001, 91, 67-74.	1.0	19
87	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69266.	1.1	19
88	Factors Associated With Access to HIV Testing and Primary Care Among Migrants Living in Europe: Cross-Sectional Survey. <i>JMIR Public Health and Surveillance</i> , 2017, 3, e84.	1.2	19
89	Association of Clinical Progression in Classic Kaposi's Sarcoma With Reduction of Peripheral B Lymphocytes and Partial Increase in Serum Immune Activation Markers. <i>Archives of Dermatology</i> , 2005, 141, 1421-6.	1.7	18
90	Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. <i>Lancet HIV</i> , 2014, 1, e41-e48.	2.1	17

#	ARTICLE	IF	CITATIONS
91	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. <i>Clinical Infectious Diseases</i> , 2012, 54, 111-118.	2.9	16
92	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	2.9	16
93	Advancing Migrant Access to Health Services in Europe (AMASE): Protocol for a Cross-sectional Study. <i>JMIR Research Protocols</i> , 2016, 5, e74.	0.5	16
94	Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals. <i>HIV Clinical Trials</i> , 2001, 2, 6-16.	2.0	15
95	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	1.0	15
96	Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1979-1997.	0.7	15
97	What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. <i>HIV Medicine</i> , 2020, 21, 3-16.	1.0	15
98	Longitudinal and Time-to-Drop-Out Joint Models Can Lead to Seriously Biased Estimates When the Drop-Out Mechanism is at Random. <i>Biometrics</i> , 2019, 75, 58-68.	0.8	14
99	National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population. <i>JMIR Research Protocols</i> , 2019, 8, e10997.	0.5	14
100	Validation of the Patient Health Questionnaire-4 (PHQ-4) to screen for depression and anxiety in the Greek general population. <i>Journal of Psychosomatic Research</i> , 2022, 160, 110970.	1.2	14
101	Performance of the marginal structural models under various scenarios of incomplete marker's values: A simulation study. <i>Biometrical Journal</i> , 2015, 57, 254-270.	0.6	13
102	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	0.8	13
103	Seasonal Variation of Neonatal and Infant Deaths by Cause in Greece. <i>Scandinavian Journal of Public Health</i> , 1994, 22, 74-80.	0.6	12
104	Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: an example on the estimation of the HIV incubation time distribution. <i>Statistics in Medicine</i> , 2001, 20, 3667-3676.	0.8	12
105	Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients. <i>Haemophilia</i> , 2002, 8, 668-673.	1.0	12
106	A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modelled with a time-to-event outcome. <i>Statistics in Medicine</i> , 2003, 22, 3161-3175.	0.8	12
107	Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337.	0.6	12
108	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. <i>Aids</i> , 2019, 33, 1645-1655.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. PLoS ONE, 2013, 8, e71174.	1.1	12
110	Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 492-498.	0.9	11
111	HIV cascade of care in Greece: Useful insights from additional stages. PLoS ONE, 2018, 13, e0207355.	1.1	11
112	The use of a complex thermohygro-metric index in predicting adverse health effects in Athens. International Journal of Biometeorology, 1995, 38, 194-198.	1.3	10
113	Changes in T Cell Receptor Excision DNA Circle (TREC) Levels in HIV Type 1-Infected Subjects Pre- and Post-Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 47-54.	0.5	10
114	Analyzing Longitudinal Data in the Presence of Informative Dropout: The Jmre1 Command. The Stata Journal, 2010, 10, 226-251.	0.9	10
115	Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals. AIDS Research and Human Retroviruses, 2013, 29, 461-469.	0.5	10
116	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV, 2017, 4, e251-e259.	2.1	10
117	A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. Clinical Infectious Diseases, 2017, 65, 1127-1135.	2.9	10
118	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clinical Infectious Diseases, 2021, 73, 195-202.	2.9	8
119	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/μL. Journal of the International AIDS Society, 2021, 24, e25726.	1.2	8
120	Prevalence, awareness, treatment and control of hypertension in Greece: EMENO national epidemiological study. Journal of Hypertension, 2021, 39, 1034-1039.	0.3	8
121	Factors associated with severity and disease progression in chronic hepatitis C. Hepato-Gastroenterology, 1998, 45, 1678-83.	0.5	8
122	Natural history of HIV-1 infection. Clinics in Dermatology, 2000, 18, 389-399.	0.8	7
123	Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients. Haemophilia, 2005, 11, 360-365.	1.0	7
124	Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. Statistics in Medicine, 2007, 26, 5473-5485.	0.8	7
125	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	1.3	7
126	Boosted Lopinavir Versus Boosted Atazanavir Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	2.9	6

#	ARTICLE	IF	CITATIONS
127	Prevalence of diabetes and pre-diabetes in Greece. Results of the First National Survey of Morbidity and Risk Factors (EMENO) study. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108646.	1.1	6
128	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	1.9	6
129	Prevalence of tobacco smoking and association with other unhealthy lifestyle risk factors in the general population of Greece: Results from the EMENO study. <i>Tobacco Prevention and Cessation</i> , 2021, 7, 1-13.	0.2	6
130	What is the impact of systematically missing exposure data on air pollution health effect estimates?. <i>Air Quality, Atmosphere and Health</i> , 2014, 7, 415-420.	1.5	5
131	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	1.3	5
132	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	1.0	5
133	Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys. <i>JMIR Research Protocols</i> , 2020, 9, e13578.	0.5	5
134	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. <i>Hippokratia</i> , 2014, 18, 57-64.	0.3	5
135	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
136	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1363-1372.	1.1	4
137	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. <i>PLoS ONE</i> , 2018, 13, e0203601.	1.1	4
138	In Vitro Gene Transcription of <i>Listeria monocytogenes</i> After Exposure to Human Gastric and Duodenal Aspirates. <i>Journal of Food Protection</i> , 2020, 83, 89-100.	0.8	4
139	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. <i>BMC Public Health</i> , 2021, 21, 1699.	1.2	4
140	Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 469-75.	0.8	4
141	Treatment cascade of hepatitis B and C in general, migrant and Roma populations. <i>Journal of Hepatology</i> , 2017, 66, S71-S72.	1.8	3
142	Opportunistic screening for hypertension: what does it say about the true epidemiology?. <i>Journal of Human Hypertension</i> , 2022, 36, 364-369.	1.0	3
143	HIV continuum of care: bridging cross-sectional and longitudinal analyses. <i>Aids</i> , 2022, 36, 583-591.	1.0	3
144	Thyroid dysfunction in Greece: Results from the national health examination survey EMENO. <i>PLoS ONE</i> , 2022, 17, e0264388.	1.1	3

#	ARTICLE	IF	CITATIONS
145	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. <i>Journal of Chemotherapy</i> , 2012, 24, 38-47.	0.7	2
146	The cost of a late-detected outbreak among people who inject drugs. A modeling study. <i>International Journal of Drug Policy</i> , 2021, 88, 103032.	1.6	2
147	Living in Roma Settlements in Greece: Self-Perceived Health Status, Chronic Diseases and Associated Social Determinants of Health. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8403.	1.2	2
148	Estimation and comparison of rates of change in longitudinal studies with informative dropouts. <i>Statistics in Medicine</i> , 1999, 18, 1215-1233.	0.8	2
149	Total and cause-specific mortality in a population based cohort of diabetics in Greece. <i>Diabète & Métabolisme</i> , 1991, 17, 410-4.	0.3	2
150	Performance of parametric survival models under non-random interval censoring: A simulation study. <i>Computational Statistics and Data Analysis</i> , 2013, 63, 16-30.	0.7	1
151	Could the 2010 HIV outbreak in Athens, Greece have been prevented? A mathematical modeling study. <i>PLoS ONE</i> , 2021, 16, e0258267.	1.1	1
152	Misspecifying the covariance structure in a linear mixed model under MAR dropout. <i>Statistics in Medicine</i> , 2020, 39, 3027-3041.	0.8	1
153	Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. <i>Hippokratia</i> , 2016, 20, 214-221.	0.3	1
154	Rejoinder to "Biased Estimation With Shared Parameter Models in the Presence of Competing Dropout Mechanisms". <i>Biometrics</i> , 2022, 78, 407-408.	0.8	0
155	Land Use Regression Modelling of traffic-related noise in Athens, Greece for use in epidemiological studies. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0